Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia

Brain

Volumn 137, Issue 12, 2014, Pages 3200-3212

  Horga, Alejandro ^a   Pitceathly, Robert D S ^a   Blake, Julian C ^b   Woodward, Catherine E ^a   Zapater, Pedro ^c   Fratter, Carl ^d   Mudanohwo, Ese E ^a   Plant, Gordon T ^a   Houlden, Henry ^a   Sweeney, Mary G ^a   Hanna, Michael G ^a   Reilly, Mary M ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Mitochondrial DNA; Mitochondrial DNA deletion; Peripheral neuropathy; POLG; Progressive external ophthalmoplegia

Indexed keywords

MITOCHONDRIAL DNA;

ADOLESCENT; ADULT; ARTICLE; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL FEATURE; CLINICAL OBSERVATION; COHORT ANALYSIS; DECISION TREE; DEMOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FAMILY HISTORY; FEMALE; GENE DELETION; GENETIC DISORDER; GENOTYPE; HEARING IMPAIRMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUROPHYSIOLOGY; NUCLEAR GENE DEFECT; ONSET AGE; PERIPHERAL NEUROPATHY; PIGMENT DISORDER; POINT MUTATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETINOPATHY; YOUNG ADULT; CELL NUCLEUS; GENETIC PREDISPOSITION; GENETICS; MITOCHONDRION; MUTATION;

ADOLESCENT; ADULT; CELL NUCLEUS; DNA, MITOCHONDRIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; MUTATION; OPHTHALMOPLEGIA, CHRONIC PROGRESSIVE EXTERNAL; PERIPHERAL NERVOUS SYSTEM DISEASES; YOUNG ADULT;

EID: 84922367338     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awu279     Document Type: Article

References (52)

1. Agostino A, Valletta L, Chinnery PF, Ferrari G, Carrara F, Taylor RW, et al. Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology 2003; 60: 1354-6.
2. Aure K, Ogier de Baulny H, Laforet P, Jardel C, Eymard B, Lombes A. Chronic progressive ophthalmoplegia with large-scale mtDNA rearrangement: can we predict progression? Brain 2007; 130 (Pt 6): 1516-24.
3. Boles RG, Roe T, Senadheera D, Mahnovski V, Wong LJ. Mitochondrial DNA deletion with Kearns Sayre syndrome in a child with Addison disease. Eur J Pediatr 1998; 157: 643-7.
4. Brockington M, Alsanjari N, Sweeney MG, Morgan-Hughes JA, Scaravilli F, Harding AE. Kearns-Sayre syndrome associated with mito-chondrial DNA deletion or duplication: a molecular genetic and pathological study. J Neurol Sci 1995; 131: 78-87.
5. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. Brain 1997; 120 (Pt 10): 1713-21.
6. Chinnery PF, Shoubridge EA. Mitochondrial myopathies. In: Karpati G, Hilton-Jones D, Bushby K, Griggs RC, editors. Disorders of voluntary muscle. 8th edn. New York: Cambridge University Press; 2010. p. 363-89.
7. Eymard B, Penicaud A, Leger JM, Romero N, Marsac C, Fardeau M, et al. Clinical and electrophysiologic study of the peripheral nerve in 28 cases of mitochondrial disease. Rev Neurol (Paris) 1991; 147: 508-12.
8. Fadic R, Russell JA, Vedanarayanan VV, Lehar M, Kuncl RW, Johns DR. Sensory ataxic neuropathy as the presenting feature of a novel mito-chondrial disease. Neurology 1997; 49: 239-45.
9. Fratter C, Gorman GS, Stewart JD, Buddles M, Smith C, Evans J, et al. The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology 2010; 74: 1619-26.
10. Fratter C, Raman P, Alston CL, Blakely EL, Craig K, Smith C, et al. RRM2B mutations are frequent in familial PEO with multiple mtDNA deletions. Neurology 2011; 76: 2032-4.
11. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mito-chondrial neurogastrointestinal encephalomyopathy. Brain 2011; 134 (Pt 11): 3326-32.
12. Herrmann DN, Ferguson ML, Logigian EL. Conduction slowing in diabetic distal polyneuropathy. Muscle Nerve 2002; 26: 232-7.
13. Hirano M, DiMauro S. ANT1, Twinkle, POLG, and TP: new genes open our eyes to ophthalmoplegia. Neurology 2001; 57: 2163-5.
14. Holt IJ, Harding AE, Cooper JM, Schapira AH, Toscano A, Clark JB, et al. Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. Ann Neurol 1989; 26: 699-708.
15. Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428-33.
16. Horvath R, Hudson G, Ferrari G, Futterer N, Ahola S, Lamantea E, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain 2006; 129 (Pt 7): 1674-84.
17. Hudson G, Amati-Bonneau P, Blakely EL, Stewart JD, He L, Schaefer AM, et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 2008; 131 (Pt 2): 329-37.
18. Hudson G, Deschauer M, Taylor RW, Hanna MG, Fialho D, Schaefer AM, et al. POLG1, C10ORF2, and ANT1 mutations are uncommon in sporadic progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Neurology 2006; 66: 1439-41.
19. Jackson MJ, Schaefer JA, Johnson MA, Morris AA, Turnbull DM, Bindoff LA. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. Brain 1995; 118 (Pt 2): 339-57.
20. Jiménez Caballero PE, ServiáCandela M, Cabeza Álvarez CI, Álvarez Tejerina A. Chronic progressive external ophthalmoplegia: a report of 6 cases and a review of the literature. Neurologist 2007; 13: 33-6.
21. Kageyama Y, Ichikawa K, Fujioka A, Tsutsumi A, Yorifuji S, Miyoshi K. An Autopsy Case of Mitochondrial Encephalomyopathy with Prominent Degeneration in Olivo-Ponto-Cerebellar System. Acta Neuropathol (Berl) 1991; 83: 99-103.
22. Karadimas CL, Vu TH, Holve SA, Chronopoulou P, Quinzii C, Johnsen SD, et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am J Hum Genet 2006; 79: 544-8.
23. Kärppä M, Syrjälä P, Tolonen U, Majamaa K. Peripheral neuropathy in patients with the 3243A4G mutation in mitochondrial DNA. J Neurol 2003; 250: 216-21.
24. Kaufmann P, Pascual JM, Anziska Y, Gooch CL, Engelstad K, Jhung S, et al. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation. Arch Neurol 2006; 63: 746-8.
25. Lax NZ, Whittaker RG, Hepplewhite PD, Reeve AK, Blakely EL, Jaros E, et al. Sensory neuronopathy in patients harbouring recessive polymer-ase gamma mutations. Brain 2012; 135 (Pt 1): 62-71.
26. Lee AG, Brazis PW. Chronic progressive external ophthalmoplegia. Curr Neurol Neurosci Rep 2002; 2: 413-7.
27. Liu CH, Chang CH, Kuo HC, Ro LS, Liou CW, Wei YH, et al. Prognosis of symptomatic patients with the A3243G mutation of mitochondrial DNA. J Formos Med Assoc 2012; 111: 489-94.
28. Love S, Nicoll JA, Kinrade E. Sequencing and quantitative assessment of mutant and wild-type mitochondrial DNA in paraffin sections from cases of MELAS. J Pathol 1993; 170: 9-14.
29. Martikainen MH, Hinttala R, Roytta M, Jaaskelainen S, Wendelin-Saarenhovi M, Parkkola R, et al. Progressive external ophthalmoplegia in southwestern Finland: a clinical and genetic study. Neuroepidemiology 2012; 38: 114-9.
30. Molnar M, Zanssen S, Buse G, Schroder JM. A large-scale deletion of mitochondrial DNA in a case with pure mitochondrial myopathy and neuropathy. Acta Neuropathol 1996; 91: 654-8.
31. Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, et al. Mitochondrial DNA deletions in progressive external ophthalmo-plegia and Kearns-Sayre syndrome. N Engl J Med 1989; 320: 1293-9.
32. Neeve VC, Samuels DC, Bindoff LA, van den Bosch B, Van Goethem G, Smeets H, et al. What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr? Brain 2012; 135 (Pt 12): 3614-26.
33. Nesbitt V, Pitceathly RD, Turnbull DM, Taylor RW, Sweeney MG, Mudanohwo EE, et al. The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A4G mutation-implications for diagnosis and management. J Neurol Neurosurg Psychiatry 2013; 84: 936-8.
34. Park KP, Kim HS, Kim ES, Park YE, Lee CH, Kim DS. SLC25A4 and C10ORF2 Mutations in Autosomal Dominant Progressive External Ophthalmoplegia. J Clin Neurol 2011; 7: 25-30.
35. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94.
36. Pfeffer G, Gorman GS, Griffin H, Kurzawa-Akanbi M, Blakely EL, Wilson I, et al. Mutations in the SPG7 gene cause chronic progressive external ophthalmoplegia through disordered mitochondrial DNA maintenance. Brain 2014; 137 (Pt 5): 1323-36.
37. Pitceathly RD, Rahman S, Hanna MG. Single deletions in mitochondrial DNA-molecular mechanisms and disease phenotypes in clinical practice. Neuromuscul Disord 2012; 22: 577-86.
38. Pitceathly RD, Smith C, Fratter C, Alston CL, He L, Craig K, et al. Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics. Brain 2012; 135 (Pt 11): 3392-403.
39. Ponzetto C, Bresolin N, Bordoni A, Moggio M, Meola G, Bet L, et al. Kearns-Sayre syndrome: different amounts of deleted mitochondrial DNA are present in several autoptic tissues. J Neurol Sci 1990; 96: 207-10.
40. Pulkes T, Liolitsa D, Nelson IP, Hanna MG. Classical mitochondrial phenotypes without mtDNA mutations: the possible role of nuclear genes. Neurology 2003; 61: 1144-7.
41. Raffelsberger T, Rossmanith W, Thaller-Antlanger H, Bittner RE. CPEO associated with a single nucleotide deletion in the mitochondrial tRNA(Tyr) gene. Neurology 2001; 57: 2298-301.
42. Rahman S, Hanna MG. Diagnosis and therapy in neuromuscular disorders: diagnosis and new treatments in mitochondrial diseases. J Neurol Neurosurg Psychiatry 2009; 80: 943-53.
43. Reichmann H, Degoul F, Gold R, Meurers B, Ketelsen UP, Hartmann J, et al. Histological, enzymatic and mitochondrial DNA studies in patients with Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia. Eur Neurol 1991; 31: 108-13.
44. Rodríguez-Hernández M, Hirano M, Arrieta T, Lestayo Z, Estrada R, Santiesteban R, et al. [Molecular studies in Cuban patients with progressive external ophthalmoplegia]. Rev Neurol 2000; 30: 1001-5.
45. Ronchi D, Garone C, Bordoni A, Gutierrez Rios P, Calvo SE, Ripolone M, et al. Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. Brain 2012; 135 (Pt 11): 3404-15.
46. Smits BW, Hol FA, van den Heuvel LP, Drost G, Rodenburg RJ, Ter Laak HJ, et al. Chronic progressive external ophthalmoplegia caused by an m.4267A4G mutation in the mitochondrial tRNAIle. J Neurol 2007; 254: 1614-5.
47. Sweeney MG, Brockington M, Weston MJ, Morgan-Hughes JA, Harding AE. Mitochondrial DNA transfer RNA mutation Leu(UUR)A4G 3260: a second family with myopathy and cardiomy-opathy. Q J Med 1993; 86: 435-8.
48. Tang S, Wang J, Lee NC, Milone M, Halberg MC, Schmitt ES, et al. Mitochondrial DNA polymerase gamma mutations: an ever expanding molecular and clinical spectrum. J Med Genet 2011; 48: 669-81.
49. Tyynismaa H, Sun R, Ahola-Erkkila S, Almusa H, Poyhonen R, Korpela M, et al. Thymidine kinase 2 mutations in autosomal recessive progressive external ophthalmoplegia with multiple mitochondrial DNA deletions. Hum Mol Genet 2012; 21: 66-75.
50. Van Goethem G, Martin JJ, Dermaut B, Lofgren A, Wibail A, Ververken D, et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003; 13: 133-42.
51. Young MJ, Longley MJ, Li FY, Kasiviswanathan R, Wong LJ, Copeland WC. Biochemical analysis of human POLG2 variants associated with mitochondrial disease. Hum Mol Genet 2011; 20: 3052-66.
52. Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988; 38: 1339-46.